SCHEMBL52689

SCHEMBL52689

CCCCCCCCCCCCCCCCC(C[N+](C)(C)C)OP(=O)([O-])O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMPD1 P17405 3/20 0.47
SLC25A20 O43772 3/20 0.43
TP53 P04637 2/20 0.43
CYP2D6 P10635 2/20 0.43
TSHR P16473 2/20 0.43
MEN1 O00255 2/20 0.43
MAPT P10636 2/20 0.43
KMT2A Q03164 2/20 0.43
KDM4E B2RXH2 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
NFKB1 P19838 1/20 0.43
CYP2C19 P33261 1/20 0.43
THPO P40225 1/20 0.43
HIF1A Q16665 1/20 0.43
HSD17B10 Q99714 1/20 0.43
SLC6A5 Q9Y345 1/20 0.43
FDPS P14324 3/20 0.43
S1PR2 O95136 5/20 0.41
S1PR1 P21453 5/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31485403 1.00 SMPD1 (0.47) SMPD1SLC25A20TP53CYP2D6TSHR
SCHEMBL62053 1.00 SMPD1 (0.47) SMPD1SLC25A20TP53CYP2D6TSHR
SCHEMBL4638950 1.00 SMPD1 (0.47) SMPD1SLC25A20TP53CYP2D6TSHR
SCHEMBL905579 1.00 SMPD1 (0.47) SMPD1SLC25A20TP53CYP2D6TSHR
SCHEMBL418811 1.00 SMPD1 (0.47) SMPD1SLC25A20TP53CYP2D6TSHR
SCHEMBL60425 1.00 SMPD1 (0.47) SMPD1SLC25A20TP53CYP2D6TSHR
SCHEMBL60847 1.00 SMPD1 (0.47) SMPD1SLC25A20TP53CYP2D6TSHR
SCHEMBL2695073 1.00 SMPD1 (0.47) SMPD1SLC25A20TP53CYP2D6TSHR
SCHEMBL632448 1.00 SMPD1 (0.47) SMPD1SLC25A20TP53CYP2D6TSHR
SCHEMBL2693658 1.00 SMPD1 (0.47) SMPD1SLC25A20TP53CYP2D6TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 3220 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4363043-B1 COMPOSITIONS FOR USE IN METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS NOVOCURE GMBH (CH) 2026-04-22 EP claimed
US-12594421-B2 Compositions and methods for increasing cancer cell sensitivity to alternating electric fields NOVOCURE GMBH (CH) 2026-04-07 US claimed
US-20250339680-A1 COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS NOVOCURE GMBH (CH) 2025-11-06 US claimed
CN-119454909-B Formulation composition of glucagon-like peptide-1 receptor agonist for nasal mucosa administration, preparation method, application and nasal applicator 上海世领制药有限公司 2025-04-08 CN claimed
US-20250090558-A1 APPLICATION OF MILTEFOSINE IN PROMOTING BONE FORMATION AND PREVENTING-TREATING OSTEOPOROSIS The First Affiliated Hospital of Zhejiang Chinese Medical University (CN) 2025-03-20 US claimed
CN-119454909-A Formulation composition of glucagon-like peptide-1 receptor agonist for nasal mucosa administration, preparation method, application and nasal applicator 上海世领制药有限公司 2025-02-18 CN claimed
EP-3586142-B1 DETECTION OF MEMBRANE PROTEINS UNIV OXFORD INNOVATION LTD (GB) 2024-12-25 EP claimed
EP-4363043-A1 COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS Novocure GmbH (CH) 2024-05-08 EP claimed
CN-117580614-A Compositions and methods for increasing sensitivity of cancer cells to alternating electric fields 诺沃库勒有限责任公司 2024-02-20 CN claimed
US-11819508-B2 Miltefosine for the treatment of viral infections including covid-19 PROFOUNDA HEALTH AND BEAUTY INC. (US) 2023-11-21 US claimed
EP-0393575-B1 Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent SEARLE & CO (US) 1994-03-16 EP claimed
US-5290769-A Applying compositions for skin disorders ASTA PHARMA AKTIENGESELLSCHAFT (DE) 1994-03-01 US claimed
EP-0359981-B1 PHARMACEUTICAL COMBINATIONS AND THEIR USE AS ANTINEOPLASTIC MEDICINES Roche Diagnostics GmbH (DE) 1993-07-28 EP claimed
US-5049552-A Anticancer agents MAX-PLANCK-GESELLSCHAFT FUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) 1991-09-17 US claimed
EP-0248047-B1 MEDICAMENT WITH ANTI-TUMORAL ACTION CONTAINING HEXADECYLPHOSPHOCHOLINE Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 1991-06-19 EP claimed
EP-0393575-A1 Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent G.D. Searle & Co. (US) 1990-10-24 EP claimed
US-4837023-A ANTICARCINOGENIC AGENTS, ANTITUMOR AGENTS MAX-PLANCK-GESELLSCHAFT ZUR FOEDERUNG DER WISSENSCHAFTEN (DE) 1989-06-06 US claimed
EP-0248047-A1 MEDICAMENT WITH ANTI-TUMORAL ACTION CONTAINING HEXADECYLPHOSPHOCHOLINE. MAX PLANCK GESELLSCHAFT (DE) 1987-12-09 EP claimed
EP-0230575-A2 Medicament active against tumours, containing hexadecylphosphocholine Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 1987-08-05 EP claimed
WO-1987003480-A2 MEDICAMENT WITH ANTI-TUMORAL ACTION CONTAINING HEXADECYLPHOSPHOCHOLINE MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSC (DE) 1987-06-18 WO claimed